But perhaps the most astonishing outcome came from another patient: their glioblastoma appeared to shrink dramatically after just one dose. Within five days, scans showed almost total regression of the tumor—something nearly unheard of in the field.
What It Means — and What It Doesn’t (Yet)
Dr. Bryan Choi, a neurosurgeon and co-lead of the study, explained that this two-pronged approach may be the key to finally making progress against “solid tumors,” which have traditionally been more resistant to immunotherapies.
“This is about expanding the reach of immune therapies beyond blood cancers,” he said. By combining precision targeting with immune system activation, the method offers a way to attack tumors previously thought untouchable.
Still, scientists urge caution. With only three participants so far, more research is needed to confirm safety, long-term outcomes, and whether results can be replicated across larger populations.
A Small Step, A Huge Signal
As Dr. Marcela Maus, director of the Cellular Immunotherapy Program, put it: “We don’t have a cure yet—but this could be a very important first step.”
In cancer research, even a handful of successful cases can spark new possibilities. This study offers not just clinical progress, but emotional momentum—for patients, families, and the global effort to combat one of medicine’s toughest challenges.
